David Geldmacher
Neurology · Birmingham, ALNPI 1174692701
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $86,830 of the $99,055 with a category attached, or 87.7%. 7 manufacturers reported payments, led by Biogen at 28.5% of the total. Among neurology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $1053.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$28K
- Eisai Inc.$25K
- Lilly USA, LLC$21K
- Genentech USA, Inc.$13K
- Eli Lilly$6K
- Grifols Shared Services North America, Inc.$6K
- plus $80 from 1 others
Across 252 payments — averaging $10,001 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$1.4M
- Janssen Research & Development, LLC$408K
- Eisai Inc.$345K
- AbbVie$261K
- Genentech, Inc.$121K
- Eli Lilly$810
What the payments were for
- Consulting fees$86,83088%
- Travel & lodging$9,69910%
- Food & beverage$2,5263%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 11 | $28,264 |
| Eisai Inc. | 21 | $25,404 |
| Lilly USA, LLC | 41 | $20,716 |
| Genentech USA, Inc. | 11 | $13,165 |
| Eli Lilly | 2 | $5,825 |
| Grifols Shared Services North America, Inc. | 7 | $5,600 |
| F. Hoffmann-la Roche AG | 1 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADUHELM$20,759
- KISUNLA$17,292
- Albutein$4,400
- Flebogamma DIF$1,200
How this compares
$99,055 in reported general payments places this provider in the 90th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 21 | $3,929 |
| Duloxetine Hcl | 14 | $622 |
| Memantine Hcl | 13 | $263 |
| Donepezil Hcl | 30 | $242 |
| Escitalopram Oxalate | 23 | $214 |
| Quetiapine Fumarate | 15 | $205 |
| Clonazepam | 26 | $203 |
| Citalopram HbrCitalopram Hydrobromide | 46 | $188 |
| Lorazepam | 11 | $8 |
Paid to pharmacies, not to this prescriber.
Other neurology in Birmingham
- Diane CounceBirmingham$895K
- Emily RiserBirmingham$231K
- Wesley KingBirmingham$167K
- Jerzy SzaflarskiBirmingham$164K
- Victor SungBirmingham$138K
- Raymond FaughtBirmingham$99K
- David StandaertBirmingham$82K
- Richard DiethelmBirmingham$65K
- Mina LobbousBirmingham$49K
- Harrison WalkerBirmingham$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.